CD274 and melanoma: Additionally, individuals with melanoma who underwent anti-PD-1 therapy (GSE78220, Figure 10B, p = 0.012), advanced NSCLC who received anti-PD-1/PD-L1 antibody (GSE135222, Figure 10C, p = 0.031), melanoma who underwent nivolumab therapy (ICB.